Kombinationstherapie bei pulmonaler arterieller Hypertonie – Switch von Selexipag zu intravenösem Treprostinil

Zusammenfassung

Aktuell ist ein breites Spektrum von Substanzen zur Behandlung von Patienten mit pulmonaler arterieller Hypertonie verfügbar. Die aktuellen Empfehlungen orientieren sich bei der initialen medikamentösen Therapie an dem Risiko der Patienten. Bei Patienten mit hohem Risiko wird schon initial eine Triple-Kombination verschiedener Substanzen unter Einbeziehung von Prostanoiden empfohlen.

In der prospektiven, einarmigen, unverblindeten Studie sollte geklärt werden, ob PAH-Patienten unter einer Triple-Therapie von der Umstellung von Selexipag auf intravenöses Treprostinil profitieren. Primärer Endpunkt war das Erreichen eines „Low-Risk“-Status nach 6 (12) Monaten.

Es wurden 27 PAH-Patienten (45 [37; 61] Jahre, 77,8% Frauen) eingeschlossen. Bei Studienbeginn wurden sie einem „Low-Risk“- (n=1), „Intermediate“- (n=12) oder „High-Risk“-Status (n=14) zugeordnet. Eine Verlaufsbeobachtung erfolgte im Mittel über 8 (Spanne 5–11) Monate bei 22 Patienten. Ein Patient wurde nach 4 Monaten erfolgreich transplantiert, weitere 4 Patienten verstarben (in 1 Fall septische Komplikationen unklarer Genese; in 3 Fällen progredientes Rechtsherzversagen). Der primäre Endpunkt (Erreichen des „Low-Risk“-Status) wurde von 12/21 (57,1%) Patienten erreicht (ein weiterer Patient verblieb im „Low-Risk“-Status).

Diese Daten geben (trotz der geringen Zahl von Patienten) einen Hinweis darauf, dass auch bei etablierter Triple-Therapie durch den Wechsel von Selexipag auf intravenöses Treprostinil eine klinische Verbesserung einzelner Patienten möglich ist.

Abstract

A wide range of substances is currently available for the treatment of patients with pulmonary arterial hypertension. The current recommendations for initial drug therapy are based on the patient’s risk profile. For patients at high risk, an initial triple combination therapy with different substances including prostanoids is recommended.

The aim of the prospective, single-arm, unblinded study was to clarify whether PAH patients on triple therapy benefit from switching from selexipag to intravenous treprostinil. The primary endpoint was the achievement of a “low-risk” status after 6 (12) months.

27 PAH patients (45 (37; 61) years, 77.8% women) were included. At study entry they were assigned to low-risk (n=1), intermediate (n=12) or high-risk status (n=14). On average, 22 patients were followed for 8 (range 5–11) months. One patient was successfully transplanted after four months, another four patients died (in one case septic complications of unknown origin; in three cases progressive right heart failure). The primary endpoint (reaching “low-risk” status) was achieved in 12/21 (57.1%) patients (one further patient remained in “low-risk” status).

These data indicate (despite the small number of patients) that even with established triple therapy, clinical improvement in individual patients is possible by switching from selexipag to intravenous treprostinil.

Schlüsselwörter

pulmonal arterielle Hypertonie - Risikostratifizierung - Selexipag - intravenöses Treprostil - Medikamentenpumpe

Keywords

pulmonary hypertension - risk stratification - elexipaq - intravenous trepostinil - drug pump

Publication History

Received: 19 September 2024

Accepted after revision: 13 November 2024

Article published online:
04 December 2024

• Literatur

• 1 Humbert M, Kovasc G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-3731
• 2 Galié N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119
• 3 Olsson KM, Richter MJ, Kamp JC. et al. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2019; 38: 748-756
• 4 Sitbon O, Jais X, Savale L. et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-1697
• 5 Bartolome S, Sood N, Shah TG. et al. Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. Chest 2018; 154: 532-540
• 6 Gomberg-Maitland M, Bourge RC, Shapiro SM. et al. Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. Pulm Circ 2019; 9 2045894019878615
• 7 Bourge RC, Waxman AB, Gomberg-Maitland M. et al. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest 2016; 150: 27-34
• 8 Wang S, Yan Y, Zhang J. et al. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta-analysis. Anim Models Exp Med 2024; 7: 56-70
• 9 Hoeper MM, Kramer T, Pan Z. et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740
• 10 Hjalmarsson C, Radegran G, Kylhammar D. et al. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J 2018; 51: 1702310
• 11 Boucly A, Weatherald J, Savale L. et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889
• 12 Rosenkranz S, Pausch C, Coghlan JG. et al. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. J Heart Lung Transpl 2023; 42: 102-114
• 13 Coghlan JG, Gaine S, Channick R. et al. Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension. ERJ Open Res 2023; 9: 00456-2022
• 14 Qin J, Wang G, Han D. Selexipag in Patients With Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Probl Cardiol 2023; 48: 101466
• 15 Kim NH, Hemnes AR, Chakinala MM. et al. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant 2021; 40: 279-288
• 16 Ewert R, Halank M, Bruch L. et al. A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy. Am J Respir Crit Care Med 2012; 186: 1196-1198
• 17 Ewert R, Richter MJ, Steringer-Mascherbauer R. et al. Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clin Res Cardiol 2017; 106: 776-783
• 18 Richter MJ, Harutyunova S, Bollmann T. et al. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant 2018; 37: 1235-1244
• 19 Richter M, Ewert R, Warnke C. et al. Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. Clin Res Cardiol 2017; 106: 174-182
• 20 Harutyunova S, Benjamin N, Eichstaedt C. et al. Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension. Respiration 2023; 102: 579-590